Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One?

Front Immunol. 2021 Aug 31:12:668221. doi: 10.3389/fimmu.2021.668221. eCollection 2021.

Abstract

Tumor-immune interactions are often framed as predator-prey. This imperfect analogy describes how immune cells (the predators) hunt and kill immunogenic tumor cells (the prey). It allows for evaluation of tumor cell populations that change over time during immunoediting and it also considers how the immune system changes in response to these alterations. However, two aspects of predator-prey type models are not typically observed in immuno-oncology. The first concerns the conversion of prey killed into predator biomass. In standard predator-prey models, the predator relies on the prey for nutrients, while in the tumor microenvironment the predator and prey compete for resources (e.g. glucose). The second concerns oscillatory dynamics. Standard predator-prey models can show a perpetual cycling in both prey and predator population sizes, while in oncology we see increases in tumor volume and decreases in infiltrating immune cell populations. Here we discuss the applicability of predator-prey models in the context of cancer immunology and evaluate possible causes for discrepancies. Key processes include "safety in numbers", resource availability, time delays, interference competition, and immunoediting. Finally, we propose a way forward to reconcile differences between model predictions and empirical observations. The immune system is not just predator-prey. Like natural food webs, the immune-tumor community of cell types forms an immune-web of different and identifiable interactions.

Keywords: cancer ecology; first principles; immune-web; immunoediting; predator-prey dynamics; tumor-immune interactions.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / therapeutic use
  • Cell Communication / immunology*
  • Cell Death
  • Drug Resistance, Neoplasm / immunology
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy
  • Models, Immunological*
  • Neoplasms / drug therapy
  • Neoplasms / genetics
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Tumor Escape*
  • Tumor Microenvironment / immunology*

Substances

  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors